NOD-like receptors in autoimmune diseases

doi:10.1038/s41401-020-00603-2

	NOD-like receptors in autoimmune diseases
	Chen, Li 1,2; Cao, Shi-qi 1,2; Lin, Ze-min 1; He, Shi-jun 1,2; Zuo, Jian-ping 1,2,3
刊名	ACTA PHARMACOLOGICA SINICA
	2021-02-15
页码	15
关键词	pattern recognition receptors NOD-like receptors autoimmune diseases inflammasomes inhibitors botanicals
ISSN号	1671-4083
DOI	10.1038/s41401-020-00603-2
通讯作者	He, Shi-jun(heshijun@simm.ac.cn) ; Zuo, Jian-ping(jpzuo@simm.ac.cn)
英文摘要	Autoimmune diseases are chronic immune diseases characterized by dysregulation of immune system, which ultimately results in a disruption in self-antigen tolerance. Cumulative data show that nucleotide-binding and oligomerization domain (NOD)-like receptors (NLRs) play essential roles in various autoimmune diseases, such as inflammatory bowel disease (IBD), rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), psoriasis, multiple sclerosis (MS), etc. NLR proteins, consisting of a C-terminal leucine-rich repeat (LRR), a central nucleotide-binding domain, and an N-terminal effector domain, form a group of pattern recognition receptors (PRRs) that mediate the immune response by specifically recognizing cellular pathogen-associated molecular patterns (PAMPs) or damage-associated molecular patterns (DAMPs) and triggering numerous signaling pathways, including RIP2 kinase, caspase-1, nuclear factor kappa B (NF-kappa B), mitogen-activated protein kinase (MAPK) and so on. Based on their N-terminal domain, NLRs are divided into five subfamilies: NLRA, NLRB, NLRC, NLRP, and NLRX1. In this review, we briefly describe the structures and signaling pathways of NLRs, summarize the recent progress on NLR signaling in the occurrence and development of autoimmune diseases, as well as highlight numerous natural products and synthetic compounds targeting NLRs for the treatment of autoimmune diseases.
资助项目	National Natural Science Foundation of China (NSFC)[81903882] ; National Natural Science Foundation of China (NSFC)[81871240] ; National Science & Technology Major Project New Drug Creation and Manufacturing Program[2018ZX09711002-014-001] ; Personalized Medicines-Molecular Signature-based Drug Discovery and Development, Strategic Priority Research Program of the Chinese Academy of Sciences[XDA12020369]
WOS研究方向	Chemistry ; Pharmacology & Pharmacy
语种	英语
出版者	NATURE PUBLISHING GROUP
WOS记录号	WOS:000618146000002
内容类型	期刊论文
源URL	[http://119.78.100.183/handle/2S10ELR8/295746]
专题	中国科学院上海药物研究所
通讯作者	He, Shi-jun; Zuo, Jian-ping
作者单位	1.Chinese Acad Sci, Shanghai Inst Mat Med, Lab Immunopharmacol, State Key Lab Drug Res, Shanghai 201203, Peoples R China 2.Univ Chinese Acad Sci, Beijing 100049, Peoples R China 3.Shanghai Univ Tradit Chinese Med, Lab Immunol & Virol, Shanghai 201203, Peoples R China
推荐引用方式 GB/T 7714	Chen, Li,Cao, Shi-qi,Lin, Ze-min,et al. NOD-like receptors in autoimmune diseases[J]. ACTA PHARMACOLOGICA SINICA,2021:15.
APA	Chen, Li,Cao, Shi-qi,Lin, Ze-min,He, Shi-jun,&Zuo, Jian-ping.(2021).NOD-like receptors in autoimmune diseases.ACTA PHARMACOLOGICA SINICA,15.
MLA	Chen, Li,et al."NOD-like receptors in autoimmune diseases".ACTA PHARMACOLOGICA SINICA (2021):15.